Hematopoietic-Cell Transplantation at 50

New England Journal of Medicine
357, 1472-1475
DOI: 10.1056/nejmp078166

Citation Report

#	Article	IF	Citations
1	Some Dynamic Aspects of Hematopoietic Stem Cells. Stem Cell Reviews and Reports, 2008, 4, 57-64.	5.6	1
3	Oral graftâ€versusâ€host disease. Oral Diseases, 2008, 14, 396-412.	1.5	105
4	Pulmonary veno-occlusive disease following hematopoietic stem cell transplantation: a rare model of endothelial dysfunction. Bone Marrow Transplantation, 2008, 41, 677-686.	1.3	77
5	When should liver biopsy be performed after hematopoietic stem cell transplantation?. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, 167-169.	1.4	16
6	Phagocytes Defects. , 2008, , 131-166.		6
7	Primary Immunodeficiency Diseases. , 2008, , .		23
8	Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation. Journal of Autoimmunity, 2008, 30, 172-179.	3.0	58
9	Psychosocial considerations in hematopoietic stem cell transplantation: implications for patient quality of life and post-transplant survival. Community Oncology, 2008, 5, 407-411.	0.2	7
10	The Impact of the German Tissue Act on the Manufacturing of Autologous and Allogeneic Stem Cell Preparations. Transfusion Medicine and Hemotherapy, 2008, 35, 446-452.	0.7	8
11	Fungal infections in hematopoietic stem cell transplant recipients. Medical Mycology, 2008, 46, 293-302.	0.3	71
12	High-Dose Etoposide: From Phase I to a Component of Curative Therapy. Journal of Clinical Oncology, 2008, 26, 5310-5312.	0.8	4
13	Stem Cells Bioprocessing: An Important Milestone to Move Regenerative Medicine Research Into the Clinical Arena. Pediatric Research, 2008, 63, 461-466.	1.1	37
14	Technology Insight: hematopoietic stem cell transplantation for systemic rheumatic disease. Nature Clinical Practice Rheumatology, 2008, 4, 184-191.	3.2	12
15	Allogeneic stem cell transplantation for thalassemia major. Haematologica, 2008, 93, 1780-1784.	1.7	59
16	Mesenchymal Stem Cell Transplantation for Neurodegenerative Diseases. Cell Transplantation, 2008, 17, 1103-1113.	1.2	110
17	Development of gene therapy for blood disorders. Blood, 2008, 111, 4431-4444.	0.6	65
18	THE POTENTIAL OF PLURIPOTENT CELLS IN VITREORETINAL DISEASES. Retina, 2008, 28, 1031-1034.	1.0	9
19	Phenotypic Evolutionary Models in Stem Cell Biology: Replacement, Quiescence, and Variability. PLoS ONE, 2008, 3, e1591.	1.1	38

#	Article	IF	Citations
21	A Chimerism-Based Approach to Induce Tolerance in IgE-Mediated Allergy. Critical Reviews in Immunology, 2009, 29, 379-397.	1.0	7
22	Losing the genetic twin: donor grief after unsuccessful unrelated stem cell transplantation. BMC Health Services Research, 2009, 9, 2.	0.9	11
23	Infection prevention strategies in a stem cell transplant unit: impact of change of care in isolation practice and routine use of high dose intravenous immunoglobulins on infectious complications and transplant related mortality. European Journal of Haematology, 2009, 83, 130-138.	1.1	10
24	Regenerative medicine: A primer for paediatricians. Early Human Development, 2009, 85, 685-689.	0.8	5
25	Risk score for outcome after allogeneic hematopoietic stem cell transplantation. Cancer, 2009, 115, 4715-4726.	2.0	337
26	Cord blood banking: â€˜providing cord blood banking for a nationâ€™. British Journal of Haematology, 2009, 147, 227-235.	1.2	51
27	History of Hematopoietic Stem Cell Transplantation. Seminars in Oncology Nursing, 2009, 25, 95-99.	0.7	17
28	Introduction. Seminars in Oncology Nursing, 2009, 25, 93-94.	0.7	0
29	Port-wine-flavour bone-marrow sandwiches and beyond. Lancet Oncology, The, 2009, 10, 926.	5.1	2
30	Allogeneic blood stem cell transplantation. European Journal of Cancer, 2009, 45, 412-413.	1.3	0
31	Hurdles to the Induction of Tolerogenic Mixed Chimerism. Transplantation, 2009, 87, S79-S84.	0.5	10
32	Trends of hematopoietic stem cell transplantation in the third millennium. Current Opinion in Hematology, 2009, 16, 420-426.	1.2	43
33	Incidence and Trends. , 0, , 46-55.		5
34	Isolation and Characterization of Mesenchymal Stromal Cells From Human Degenerated Nucleus Pulposus. Spine, 2010, 35, 2259-2265.	1.0	178
35	High-dose cyclophosphamide for graft-versus-host disease prevention. Current Opinion in Hematology, 2010, 17, 493-499.	1.2	84
36	Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood, 2010, 115, 925-935.	0.6	721
37	High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood, 2010, 115, 3224-3230.	0.6	346
38	Concise Review: Hitting the Right Spot with Mesenchymal Stromal Cells Â. Stem Cells, 2010, 28, 1446-1455.	1.4	348

#	Article	IF	Citations
39	Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer. Nature Reviews Cancer, 2010, 10, 213-221.	12.8	245
40	Intravenous apoptotic cell infusion as a cellâ€based therapy toward improving hematopoietic cell transplantation outcome. Annals of the New York Academy of Sciences, 2010, 1209, 118-126.	1.8	14
41	How do I collect and process stem cells?. ISBT Science Series, 2010, 5, 136-140.	1.1	0
43	Transfusion dansÂlesÂgreffes deÂcellules souches hÃ©matopoÃ¯Ã©tiques. Hematologie, 2010, 16, 47-54.	0.0	4
44	A Survey on Cellular and Engineered Tissue Therapies in Europe in 2008. Tissue Engineering - Part A, 2010, 16, 2419-2427.	1.6	23
45	Hematopoietic Stem Cell Transplantation<subtitle>A Global Perspective</subtitle>. JAMA - Journal of the American Medical Association, 2010, 303, 1617.	3.8	556
46	Hematopoietic Stem Cell Transplantation in Thalassemia. Hematology American Society of Hematology Education Program, 2010, 2010, 456-462.	0.9	79
47	Regenerative medicine. Opportunities and challenges: a brief overview. Journal of the Royal Society Interface, 2010, 7, S777-81.	1.5	34
48	Transplantation immunology: Solid organ and bone marrow. Journal of Allergy and Clinical Immunology, 2010, 125, S324-S335.	1.5	139
49	Evidence for a Bidirectional Relationship between Cytomegalovirus Replication and acute Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2010, 16, 1309-1314.	2.0	213
50	European survey on clinical use of cord blood for hematopoietic and non-hematopoietic indications. Transfusion and Apheresis Science, 2010, 42, 265-275.	0.5	16
51	CD34+ cell selection using small-volume marrow aspirates: a platform for novel cell therapies and regenerative medicine. Cytotherapy, 2010, 12, 170-177.	0.3	7
52	Novel Transplant Strategies in Adults with Acute Leukemia. Hematology/Oncology Clinics of North America, 2011, 25, 1319-1339.	0.9	0
53	The effect of local breast radiotherapy on circulating CD34+ cells. Radiotherapy and Oncology, 2011, 100, 304-307.	0.3	2
54	Cord Blood Transplantation in Adults with Acute Leukemia. , 2011, , .		0
55	Delivery of Therapeutics: Current Status and Its Relevance to Regenerative Innovations. Recent Patents on Nanomedicine, 2011, 1, 7-18.	0.5	7
56	Swiss Blood Stem Cells: More than Just a Registry. Transfusion Medicine and Hemotherapy, 2011, 38, 300-307.	0.7	1
57	Testes de funÃ§Ã£o pulmonar e mortalidade apÃ³s o transplante de cÃ©lulas-tronco hematopoiÃ©ticas. Jornal Brasileiro De Pneumologia, 2011, 37, 598-606.	0.4	2

#	Article	IF	Citations
58	Support of Unrelated Stem Cell Donor Searches by Donor Center-Initiated HLA Typing of Potentially Matching Donors. PLoS ONE, 2011, 6, e20268.	1.1	9
59	The Ins and Outs of Hematopoietic Stem Cells: Studies to Improve Transplantation Outcomes. Stem Cell Reviews and Reports, 2011, 7, 590-607.	5.6	59
60	Defining the hematopoietic stem cell niche: The chicken and the egg conundrum. Journal of Cellular Biochemistry, 2011, 112, 1486-1490.	1.2	8
61	Modelling hematopoiesis in health and disease. Mathematical and Computer Modelling, 2011, 53, 1546-1557.	2.0	16
62	The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplantation, 2011, 46, 485-501.	1.3	133
63	Immunization of hematopoietic stem cell transplant recipients against vaccine-preventable diseases. Expert Review of Clinical Immunology, 2011, 7, 193-203.	1.3	26
64	Introduction of a Quality Management System and Outcome After Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2011, 29, 1980-1986.	0.8	85
65	Diabetes Impairs Hematopoietic Stem Cell Mobilization by Altering Niche Function. Science Translational Medicine, 2011, 3, 104ra101.	5.8	254
66	The EBMT activity survey 2008: impact of team size, team density and new trends. Bone Marrow Transplantation, 2011, 46, 174-191.	1.3	53
67	Donor- but not host-derived interleukin-10 contributes to the regulation of experimental graft-versus-host disease. Journal of Leukocyte Biology, 2012, 91, 667-675.	1.5	29
68	Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 564-569.	3.3	125
69	Therapeutic Efficacy of Cord Blood-Derived Mesenchymal Stromal Cells for the Prevention of Acute Graft-Versus-Host Disease in a Xenogenic Mouse Model. Stem Cells and Development, 2012, 21, 1616-1626.	1.1	42
71	Adoptive cellular immunotherapy. , 0, , 582-592.		0
72	Course and management of allogeneic stem cell transplantation in patients with mitochondrial neurogastrointestinal encephalomyopathy. Journal of Neurology, 2012, 259, 2699-2706.	1.8	52
73	Functional status and health-related quality of life among allogeneic transplant patients at hospital discharge: a comparison of sociodemographic, disease, and treatment characteristics. Supportive Care in Cancer, 2012, 20, 2697-2704.	1.0	14
74	American Society of Blood and Marrow Transplantation Guidelines for Training in Hematopoietic Progenitor Cell Transplantation. Biology of Blood and Marrow Transplantation, 2012, 18, 1322-1328.	2.0	7
75	The Effect of Folinic Acid on Methylenetetrahydrofolate Reductase Polymorphisms in Methotrexate-Treated Allogeneic Hematopoietic Stem Cell Transplants. Biology of Blood and Marrow Transplantation, 2012, 18, 722-730.	2.0	9
76	Management of severe epidermolysis bullosa by haematopoietic transplant: principles, perspectives and pitfalls. Experimental Dermatology, 2012, 21, 896-900.	1.4	20

#	Article	IF	Citations
77	The EBMT activity survey: 1990â€“2010. Bone Marrow Transplantation, 2012, 47, 906-923.	1.3	174
78	History of Hematopoietic Stem Cell Transplantation: Evolution and Perspectives. Current Problems in Dermatology, 2012, 43, 81-90.	0.8	20
79	Spermatogonial Stem Cell Transplantation into Rhesus Testes Regenerates Spermatogenesis Producing Functional Sperm. Cell Stem Cell, 2012, 11, 715-726.	5.2	359
80	Regenerative Therapy Using Blood-Derived Stem Cells. , 2012, , .		2
81	New approaches to expand hematopoietic stem and progenitor cells. Expert Opinion on Biological Therapy, 2012, 12, 743-756.	1.4	12
82	Your time starts now â€" translation time lines for major ophthalmic discoveries. Medical Journal of Australia, 2012, 196, 672-674.	0.8	1
83	Are we making progress in GVHD prophylaxis and treatment?. Hematology American Society of Hematology Education Program, 2012, 2012, 251-264.	0.9	40
84	Exploring the Human Term Placenta as a Novel Source for Stem Cells and their Application in the Clinic. , 0, , .		2
85	Safety and efficacy of healthy volunteer stem cell mobilization with filgrastim Gâ€CSF and mobilized stem cell apheresis: results of a prospective longitudinal 5â€year followâ€up study. Vox Sanguinis, 2013, 104, 46-54.	0.7	45
86	Finding ways to improve the use of biobanks. Nature Medicine, 2013, 19, 814-815.	15.2	10
87	Stem cell biology is population biology: differentiation of hematopoietic multipotent progenitors to common lymphoid and myeloid progenitors. Theoretical Biology and Medical Modelling, 2013, 10, 5.	2.1	22
88	Mouse Models in Bone Marrow Transplantation and Adoptive Cellular Therapy. Seminars in Hematology, 2013, 50, 131-144.	1.8	10
89	Reply to MSCs: science and trials. Nature Medicine, 2013, 19, 813-814.	15.2	11
90	Regulation of stem cell therapies under attack in Europe: for whom the bell tolls. EMBO Journal, 2013, 32, 1489-1495.	3.5	79
91	Allogeneic blood and bone marrow cells for the treatment of severe epidermolysis bullosa: repair of the extracellular matrix. Lancet, The, 2013, 382, 1214-1223.	6.3	75
92	Effect of novel proteasome and immunoproteasome inhibitors on dendritic cell maturation, function, and expression of IÎºB and NFÎºB. Transplant Immunology, 2013, 29, 1-6.	0.6	5
93	The evolving art of hematopoietic stem cell transplantation: translational research in post-transplant immune reconstitution and immunosuppression. Immunologic Research, 2013, 57, 140-150.	1.3	11
94	Birth Order and Transplantation Outcome in HLA-Identical Sibling Stem Cell Transplantation: An Analysis on Behalf ofÂthe Center for International Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2013, 19, 741-745.	2.0	6

#	Article	IF	Citations
95	Gene therapy on the move. EMBO Molecular Medicine, 2013, 5, 1642-1661.	3.3	238
96	The Survey on Cellular and Engineered Tissue Therapies in Europe in 2011. Tissue Engineering - Part A, 2013, 20, 131108064828001.	1.6	39
97	Mesenchymal Stem Cells and Haematopoietic Stem Cell Culture. , 2013, , 161-172.		1
98	Notch signaling in hematopoietic cell transplantation and T cell alloimmunity. Blood Reviews, 2013, 27, 269-277.	2.8	12
99	Pharmacists and Physicians in Hematopoietic Stem Cell Transplantation: Advances and Opportunities to Use Collaborative Practice Agreements to Improve Care. Biology of Blood and Marrow Transplantation, 2013, 19, 505-506.	2.0	6
100	Effects of exercise in patients treated with stem cell transplantation for a hematologic malignancy: A systematic review and meta-analysis. Cancer Treatment Reviews, 2013, 39, 682-690.	3.4	121
102	Translating genome engineering to better clinical outcomes. Translational Research, 2013, 161, 199-204.	2.2	3
103	Epidermal growth factor regulates hematopoietic regeneration after radiation injury. Nature Medicine, 2013, 19, 295-304.	15.2	151
104	History of Multiple Myeloma. , 2013, , 521-533.		0
105	Patient-Specific Pluripotent Stem Cells. , 2013, , 381-390.		0
106	Special Care of Blood and Marrow Stem Transplant Patients. , 2013, , 1321-1345.		0
108	Quantitative and qualitative differences in use and trends of hematopoietic stem cell transplantation: a Global Observational Study. Haematologica, 2013, 98, 1282-1290.	1.7	110
109	In vitro expansion of Lin+ and Linâ^' mononuclear cells from human peripheral blood. , 2013, , .		1
110	Sicca symptoms and their impact on quality of life among very long-term survivors after hematopoietic SCT. Bone Marrow Transplantation, 2013, 48, 988-993.	1.3	20
111	Implementation of JACIE accreditation results in the establishment of new indicators that unevenly monitor processes contributing to the delivery of hematopoietic SCT. Bone Marrow Transplantation, 2013, 48, 604-609.	1.3	6
112	Hematopoietic Growth Factors in Transfusion Medicine and Cellular Therapy - Part II. Transfusion Medicine and Hemotherapy, 2013, 40, 300-301.	0.7	0
113	The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation, 2013, 48, 238-242.	1.3	25
114	Hematopoietic stem cell transplantation activity in Europe. Current Opinion in Hematology, 2013, 20, 485-493.	1.2	53

#	Article	IF	Citations
115	Increasing Hematopoietic Stem Cell Yield to Develop Mice with Human Immune Systems. BioMed Research International, 2013, 2013, 1-11.	0.9	9
116	Hematopoietic SCT in Europe: data and trends in 2011. Bone Marrow Transplantation, 2013, 48, 1161-1167.	1.3	110
117	Host-derived CD8+ dendritic cells are required for induction of optimal graft-versus-tumor responses after experimental allogeneic bone marrow transplantation. Blood, 2013, 121, 4231-4241.	0.6	34
118	Vaccination of Hematopoietic Stem Cell Transplantation Recipients: Perspective in Korea. Infection and Chemotherapy, 2013, 45, 272.	1.0	6
119	Hematopoietic Growth Factors in Transfusion Medicine and Cellular Therapy - Part I. Transfusion Medicine and Hemotherapy, 2013, 40, 223-224.	0.7	0
121	Toward an Optimal Global Stem Cell Donor Recruitment Strategy. PLoS ONE, 2014, 9, e86605.	1.1	38
122	Use of the quality management system "JACIE" and outcome after hematopoietic stem cell transplantation. Haematologica, 2014, 99, 908-915.	1.7	83
123	Here comes the cord. Blood Research, 2014, 49, 209.	0.5	0
125	Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation. Bone Marrow Transplantation, 2014, 49, 744-750.	1.3	145
126	Salvage therapy with everolimus reduces the severity of treatment-refractory chronic GVHD without impairing disease control: A dual center retrospective analysis. Bone Marrow Transplantation, 2014, 49, 1412-1418.	1.3	21
128	On Medawar's â€˜Actively acquired tolerance of foreign cellsâ€™. Experimental Dermatology, 2014, 23, 97-98.	1.4	1
129	Hematopoietic Stem Cell Transplantationâ€”50 Years of Evolution and Future Perspectives. Rambam Maimonides Medical Journal, 2014, 5, e0028.	0.4	137
130	Graft-versus-host disease. Current Opinion in Hematology, 2014, 21, 141-147.	1.2	41
131	Truth-telling and hematopoietic stem cell transplantation. Nursing Ethics, 2014, 21, 518-529.	1.8	10
132	Mechanisms for reduced pulmonary diffusing capacity in haematopoietic stem-cell transplantation recipients. Respiratory Physiology and Neurobiology, 2014, 194, 54-61.	0.7	9
133	Post-transplant cyclophosphamide and bortezomib inhibit dendritic cell maturation and function and alter their Iº B and NFº B. Transplant Immunology, 2014, 30, 40-45.	0.6	11
134	Concise Review: Umbilical Cord Blood Transplantation: Past, Present, and Future. Stem Cells Translational Medicine, 2014, 3, 1435-1443.	1.6	75
135	Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. The Cochrane Library, 2014, 2014, CD010189.	1.5	73

#	Article	IF	Citations
137	Pattern and associated factors of potential drug-drug interactions in both pre- and early post-hematopoietic stem cell transplantation stages at a referral center in the Middle East. Annals of Hematology, 2014, 93, 1913-1922.	0.8	10
138	The global landscape of stem cell clinical trials. Regenerative Medicine, 2014, 9, 27-39.	0.8	143
139	Stem-cell transplantation for chronic granulomatous disease. Lancet, The, 2014, 383, 390-392.	6.3	5
140	Single Infusion of Donor Mononuclear Early Apoptotic Cells as Prophylaxis for Graft-versus-Host Disease in Myeloablative HLA-Matched Allogeneic Bone Marrow Transplantation: A Phase I/IIa Clinical Trial. Biology of Blood and Marrow Transplantation, 2014, 20, 58-65.	2.0	50
141	Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice. Blood, 2014, 124, 2131-2141.	0.6	162
142	Delta-1 provides pleasant stem cell environs. Blood, 2014, 123, 605-606.	0.6	1
143	Î±-1-Antitrypsin (AAT)â€“modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics. Blood, 2014, 124, 2881-2891.	0.6	54
145	CE. American Journal of Nursing, 2015, 115, 22-34.	0.2	13
146	Stem Cell Transplantation. , 2015, , 651-675.		1
147	Discovery of novel INK4C small-molecule inhibitors to promote human and murine hematopoietic stem cell ex vivo expansion. Scientific Reports, 2015, 5, 18115.	1.6	18
148	Where is the common ground between bone marrow mesenchymal stem/stromal cells from different donors and species?. Stem Cell Research and Therapy, 2015, 6, 143.	2.4	47
149	Assessment of immature platelet fraction and immature reticulocyte fraction as predictors of engraftment after hematopoietic stem cell transplantation. International Journal of Laboratory Hematology, 2015, 37, 259-264.	0.7	19
150	Mobilization of hematopoietic progenitor stem cells in allogeneic setting with lenograstim by subcutaneous injection, in daily or twiceâ€daily dosing: a singleâ€center prospective study with historical control. Transfusion, 2015, 55, 2032-2038.	0.8	6
151	[18 F]FHBG PET/CT Imaging of CD34-TK75 Transduced Donor T Cells in Relapsed Allogeneic Stem Cell Transplant Patients: Safety and Feasibility. Molecular Therapy, 2015, 23, 1110-1122.	3.7	18
152	The potential of cytotherapeutics in hematologic reconstitution and in the treatment and prophylaxis of graft-versus-host disease. Chapter II: emerging transformational cytotherapies. Regenerative Medicine, 2015, 10, 345-373.	0.8	8
153	Regulation of advanced therapy medicinal products will affect the practice of haematopoietic SCT in the near future: a perspective from the EBMT cell-processing committee. Bone Marrow Transplantation, 2015, 50, 321-323.	1.3	10
154	Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplantation, 2015, 50, 476-482.	1.3	173
155	Translating Genome Engineering to Survival. , 2015, , 1-10.		0

#	Article	IF	Citations
156	Vision-Related Quality of Life in Patients with Ocular Graft-versus-Host Disease. Ophthalmology, 2015, 122, 1669-1674.	2.5	63
157	Comparison of bone marrow versus peripheral blood allogeneic hematopoietic stem cell transplantation for hematological malignancies in adultsâ€"a systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2015, 94, 179-188.	2.0	65
158	Short Course of Post-Transplantation Cyclophosphamide and Bortezomib for Graft-versus-Host Disease Prevention after Allogeneic Peripheral Blood Stem Cell Transplantation Is Feasible and Yields Favorable Results: A Phase I Study. Biology of Blood and Marrow Transplantation, 2015, 21, 1315-1320.	2.0	17
159	The potential of cytotherapeutics in hematologic reconstitution and in the treatment and prophylaxis of graft-versus-host disease. Chapter I: current practice and remaining unmet medical needs. Regenerative Medicine, 2015, 10, 331-343.	0.8	7
160	The role of hematopoietic stem cell transplantation in chronic myeloid leukemia. Annals of Hematology, 2015, 94, 177-186.	0.8	15
162	Central Nervous System Complications and Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 606-611.	0.2	29
163	Infections in Hematology. , 2015, , .		5
164	Adiponectin and resistin in acute and chronic graft-vs-host disease patients undergoing allogeneic hematopoietic stem cell transplantation. Croatian Medical Journal, 2016, 57, 255-265.	0.2	0
165	The Role of Invariant NKT Cells in Immunity. , 2016, , 357-368.		0
166	Chimerism Analysis of Cell-Free DNA in Patients Treated with Hematopoietic Stem Cell Transplantation May Predict Early Relapse in Patients with Hematologic Malignancies. Biotechnology Research International, 2016, 2016, 1-6.	1.4	17
167	Haploidentical Stem Cell Transplantation in Adult Haematological Malignancies. Advances in Hematology, 2016, 2016, 1-16.	0.6	16
168	Acute and chronic Graft-versus-host disease after hematopoietic stem cell transplantation. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2016, 62, 44-50.	0.3	22
169	Stem cell drugs: the next generation of pharmaceutical products. Biomedical Research and Therapy, 2016, 3, .	0.3	3
170	Investigation of the Effects of an Exercise Program on Physical Functions and Activities of Daily Life in Pediatric Hematopoietic Stem Cell Transplantation. Pediatric Blood and Cancer, 2016, 63, 1643-1648.	0.8	27
172	Barriers to Effective Genome Editing of Haematopoietic Stem Cells. Current Stem Cell Reports, 2016, 2, 2-8.	0.7	0
173	Bortezomib for the prevention and treatment of graft-versus-host disease afterÂallogeneic hematopoietic stem cell transplantation. Experimental Hematology, 2016, 44, 771-777.	0.2	27
174	Donor lymphocyte infusion after allogeneic stem cell transplantation. Transfusion and Apheresis Science, 2016, 54, 345-355.	0.5	54
175	Critically ill allogeneic hematopoietic stem cell transplantation patients in the intensive care unit: reappraisal of actual prognosis. Bone Marrow Transplantation, 2016, 51, 1050-1061.	1.3	47

#	Article	IF	Citations
176	Chronic myeloid leukemia: reminiscences and dreams. Haematologica, 2016, 101, 541-558.	1.7	92
177	Reduced-dose methotrexate in combination with tacrolimus was associated with rapid engraftment and recovery from oral mucositis without affecting the incidence of GVHD. International Journal of Hematology, 2016, 104, 117-124.	0.7	7
179	Metabolism and the Control of Cell Fate Decisions and Stem Cell Renewal. Annual Review of Cell and Developmental Biology, 2016, 32, 399-409.	4.0	86
182	Inspiration amidst the challenges: the first report of successful bone marrow transplantation in the Himalayan country Nepal. British Journal of Haematology, 2016, 173, 941-942.	1.2	3
183	Thiotepaâ€based versus total body irradiationâ€based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. European Journal of Haematology, 2016, 96, 90-97.	1.1	16
184	Accreditation and regulations in cell therapy. ISBT Science Series, 2016, 11, 271-276.	1.1	3
185	Chronic Myeloid Leukemia. Hematologic Malignancies, 2016, , .	0.2	3
187	The Role of Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia. Hematologic Malignancies, 2016, , 177-196.	0.2	1
188	Ethical Considerations in Pediatric Stem Cell Donation. Biology of Blood and Marrow Transplantation, 2016, 22, 3.	2.0	1
189	Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia. Biology of Blood and Marrow Transplantation, 2016, 22, 80-85.	2.0	14
191	Hematopoietic stem cell transplantation in Europe 2014: more than 40â€‰000 transplants annually. Bone Marrow Transplantation, 2016, 51, 786-792.	1.3	338
192	Prevention of CINV in Patients Receiving High-Dose Multiple-Day Chemotherapy. , 2016, , 135-156.		0
194	Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution. Bone Marrow Transplantation, 2016, 51, 267-272.	1.3	33
195	Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years. Biology of Blood and Marrow Transplantation, 2016, 22, 910-918.	2.0	32
196	Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial. Biology of Blood and Marrow Transplantation, 2016, 22, 385-390.	2.0	151
197	Diagnosis and Therapy of Acute Myeloid Leukemia in the Era of Molecular Risk Stratification. Annual Review of Medicine, 2016, 67, 59-72.	5.0	42
198	Determinants of stimulated salivary flow among haematopoietic stem cell transplantation recipients. Clinical Oral Investigations, 2017, 21, 121-126.	1.4	9
200	East Meets Westâ€”Impact of Ethnicity on Donor Match Rates in the Ezer Mizion Bone Marrow Donor Registry. Biology of Blood and Marrow Transplantation, 2017, 23, 1381-1386.	2.0	6

#	Article	IF	Citations
201	Primary Immunodeficiency Diseases. , 2017, , .		22
202	The effect of maternal and infant factors on cord blood yield. Pediatric Blood and Cancer, 2017, 64, e26381.	0.8	10
203	Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. Nature Reviews Neurology, 2017, 13, 391-405.	4.9	207
204	Calcineurin and mTOR Inhibitorâ€“Free Post-Transplantation Cyclophosphamide and Bortezomib Combination for Graft-versus-Host Disease Prevention after Peripheral Blood Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I/II Study. Biology of Blood and Marrow Transplantation, 2017, 23, 1651-1657.	2.0	14
205	Inversion 3 Cytogenetic Abnormality in an Allogeneic Hematopoietic Cell Transplant Recipient Representative of a Donor-Derived Constitutional Abnormality. Biology of Blood and Marrow Transplantation, 2017, 23, 1582-1587.	2.0	3
206	Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplantation, 2017, 52, 811-817.	1.3	310
207	Post-Transplant Cyclophosphamide and Tacrolimusâ€“Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. Biology of Blood and Marrow Transplantation, 2017, 23, 459-466.	2.0	50
208	Post-Transplantation Cyclophosphamide and Ixazomib Combination Rescues Mice Subjected to Experimental Graft-versus-Host Disease and Is Superior to Either Agent Alone. Biology of Blood and Marrow Transplantation, 2017, 23, 255-261.	2.0	18
209	Ixazomib suppresses human dendritic cell and modulates murine graft-versus-host disease in a schedule-dependent fashion. Experimental Hematology, 2017, 48, 50-57.	0.2	14
210	Central nervous system complications after allogeneic hematopoietic stem cell transplantation. Future Oncology, 2017, 13, 2297-2312.	1.1	13
211	In Vivo Confocal Microscopy Evaluation of Ocular Surface with Graft-Versus-Host Disease-Related Dry Eye Disease. Scientific Reports, 2017, 7, 10720.	1.6	45
212	Clinical-associated characteristics and microbiological features of bloodstream nontyphoidal salmonella infection in adult patients receiving allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2017, 96, 1533-1540.	0.8	2
213	Twenty-five years of gene therapy for genetic diseases and leukemia: The road to marketing authorization of the first exÂvivo gene therapies. Journal of Autoimmunity, 2017, 85, 98-102.	3.0	0
214	Practical implementation â€“ Essential elements resource tool. Hematology/ Oncology and Stem Cell Therapy, 2017, 10, 198-202.	0.6	0
215	The Safety of Non-Expanded Multipotential Stromal Cell Therapies. Stem Cells in Clinical Applications, 2017, , 91-118.	0.4	4
216	Migration against the direction of flow is LFA-1 dependent in human hematopoietic stem and progenitor cells. Journal of Cell Science, 2017, 131, .	1.2	28
217	Immunonutrition Is Associated With a Decreased Incidence of Graftâ€Versusâ€Host Disease in Bone Marrow Transplant Recipients: A Metaâ€Analysis. Journal of Parenteral and Enteral Nutrition, 2017, 41, 1286-1292.	1.3	12
218	Graft Transit Time Has No Effect on Outcome of Unrelated Donor Hematopoietic Cell Transplants Performed in Australia and New Zealand: A Study from the Australasian Bone Marrow Transplant Recipient Registry. Biology of Blood and Marrow Transplantation, 2017, 23, 147-152.	2.0	4

#	Article	IF	Citations
219	Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT. Bone Marrow Transplantation, 2017, 52, 238-244.	1.3	15
220	Potential of Stem Cells as Regenerative Medicine: From Preface to Advancements. Critical Reviews in Eukaryotic Gene Expression, 2017, 27, 1-17.	0.4	1
221	Stem Cell Therapy on the Internet: Information Quality and Content Analysis of English Language Web Pages Returned by Google. Frontiers in ICT, 2017, 4, .	3.6	4
222	Advances in Hematopoietic Stem Cell Transplantation. Advanced Techniques in Biology & Medicine, 2017, 05, .	0.1	0
223	Biopharmaceutical Products. , 2017, , 3-21.		2
224	Conditioning regimens: Do they really matter?. , 0, , 247-257.		0
225	Biology: Critical components of hematopoietic cell transplantation. , 0, , 16-22.		0
226	Hematopoietic stem cell transplantation in its 60s: A platform for cellular therapies. Science Translational Medicine, 2018, 10, .	5.8	125
227	The hematopoietic stem cell niche: from embryo to adult. Development (Cambridge), 2018, 145, .	1.2	155
228	Risk of HLA Homozygous Cord Blood Transplantation: Implications for Induced Pluripotent Stem Cell Banking and Transplantation. Stem Cells Translational Medicine, 2018, 7, 173-179.	1.6	9
229	Have haploidentical transplants replaced umbilical cord transplants for acute leukemias?. Current Opinion in Hematology, 2018, 25, 103-111.	1.2	18
231	Critically ill allogenic HSCT patients in the intensive care unit: a systematic review and meta-analysis of prognostic factors of mortality. Bone Marrow Transplantation, 2018, 53, 1233-1241.	1.3	53
232	Is the use of unrelated donor transplantation leveling off in Europe? The 2016 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplantation, 2018, 53, 1139-1148.	1.3	117
233	General Principles of HSCT. , 2018, , 13-25.		0
234	Establishing a Hematopoietic Stem Cell Transplantation Unit. , 2018, , .		2
235	Hematopoietic Stem-Cell Transplantation in the Resource-Limited Setting: Establishing the First Bone Marrow Transplantation Unit in Bangladesh. Journal of Global Oncology, 2018, 4, 1-10.	0.5	11
236	G-CSF-primed autologous and allogeneic bone marrow for transplantation in clinical oncology. Cell content and immunological characteristics. Journal of Physics: Conference Series, 2018, 945, 012004.	0.3	0
237	Beginning of a Journey of Autologous Stem Cell Transplantation in Combined Military Hospital, Dhaka, Bangladesh. BIRDEM Medical Journal, 2018, 8, 177-180.	0.0	1

#	Article	IF	Citations
238	Hematopoietic stem cell fate through metabolic control. Experimental Hematology, 2018, 64, 1-11.	0.2	68
239	Overview and Choice of Donor of Hematopoietic Stem Cell Transplantation. , 2018, , 1591-1595.		0
240	Animal Models for Preclinical Development of Allogeneic Hematopoietic Cell Transplantation. ILAR Journal, 2018, 59, 263-275.	1.8	6
242	Hematopoietic Stem Cell Properties, Markers, and Therapeutics. , 2019, , 191-204.		1
243	Therapeutic use of regulatory T cells for graftâ€versusâ€host disease. British Journal of Haematology, 2019, 187, 25-38.	1.2	41
244	Comparative efficacy and safety of vancomycin versus teicoplanin in febrile neutropenic patients receiving hematopoietic stem cell transplantation. Journal of Clinical Pharmacy and Therapeutics, 2019, 44, 888-894.	0.7	11
245	Haploidentical Transplantation with Post-Transplant Cyclophosphamide versus Unrelated Donor Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. Biology of Blood and Marrow Transplantation, 2019, 25, 2422-2430.	2.0	37
246	A General Practitionerâ€™s Guide to Hematopoietic Stem-cell Transplantation. Current Oncology, 2019, 26, 187-191.	0.9	82
247	Counting circulating endothelial cells in allo-HSCT: an ad hoc designed polychromatic flowcytometry-based panel versus the CellSearch System. Scientific Reports, 2019, 9, 87.	1.6	8
248	Antimicrobial Stewardship: Considerations for a Transplant Center. , 2019, , 1041-1051.		0
249	Comparison of transfusion requirements in adult patients undergoing Haploidentical or singleâ€unit umbilical cord blood stem cell transplantation. European Journal of Haematology, 2019, 103, 172-177.	1.1	5
250	A new era of allogeneic hematopoietic stem cell transplantation. Seminars in Hematology, 2019, 56, 171-172.	1.8	0
251	Lipocalin-2 levels in acute and chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Experimental Hematology, 2019, 74, 25-32.e1.	0.2	1
252	The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies. Bone Marrow Transplantation, 2019, 54, 1575-1585.	1.3	129
253	DissociationsÂof oral foci of infections with infectious complications and survival after haematopoietic stem cell transplantation. PLoS ONE, 2019, 14, e0225099.	1.1	8
254	Granulocyte Colony-Stimulating Factor-Primed Unmanipulated Haploidentical Blood and Marrow Transplantation. Frontiers in Immunology, 2019, 10, 2516.	2.2	36
255	Metabolism as master of hematopoietic stem cell fate. International Journal of Hematology, 2019, 109, 18-27.	0.7	71
256	Common oral diseases in allogeneic haematopoietic stem cell transplantation (HSCT) recipients preâ€HSCT. European Journal of Haematology, 2019, 102, 351-356.	1.1	9

#	Article	IF	Citations
257	Concise Review: Modulating Cancer Immunity with Hematopoietic Stem and Progenitor Cells. Stem Cells, 2019, 37, 166-175.	1.4	17
258	Mesenchymal Stem Cell Therapy in Graft Versus Host Disease. , 2019, , 111-141.		0
259	The use of comprehensive geriatric assessment in older patients before allologeneic hematopoietic stem cell transplantation: A cross-sectional study. Journal of Geriatric Oncology, 2020, 11, 100-106.	0.5	19
260	Selective Autophagy in Normal and Malignant Hematopoiesis. Journal of Molecular Biology, 2020, 432, 261-282.	2.0	21
261	Haploidentical stem cell transplantation vs matched unrelated donor transplantation in adults with hematologic malignancies: a systematic review and meta-analysis. Hematology, 2020, 25, 356-365.	0.7	8
262	Haploidentical Hematopoietic Stem Cell Transplantation Versus Umbilical Cord Blood Transplantation in Hematologic Malignancies: A Systematic Review and Meta-Analysis. Cell Transplantation, 2020, 29, 096368972096477.	1.2	8
263	A Retrospective Comparison of DLI and gDLI for Post-Transplant Treatment. Journal of Clinical Medicine, 2020, 9, 2204.	1.0	7
264	Exercise barriers and facilitators during hematopoietic stem cell transplantation: a qualitative study. BMJ Open, 2020, 10, e037460.	0.8	6
265	Pediatric HCT in Florida (2014 â€2016): A report from the FPBCC. Pediatric Transplantation, 2020, 25, e13931.	0.5	2
266	Hematopoeitic Cell Transplantation and CAR T-Cell Therapy: Complements or Competitors?. Frontiers in Oncology, 2020, 10, 608916.	1.3	13
267	Tools and Concepts for Interrogating and Defining Cellular Identity. Cell Stem Cell, 2020, 26, 632-656.	5.2	24
268	Non-invasive Reporter Gene Imaging of Cell Therapies, including T Cells and Stem Cells. Molecular Therapy, 2020, 28, 1392-1416.	3.7	44
269	How Allogeneic Hematopoietic Stem Cell Transplantation has Evolved Over Time: 30-Yearsâ€™ Experience at a Single Institution. Acta Medica Portuguesa, 2020, 33, 116.	0.2	0
270	The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-Tâ€™s come into focus. Bone Marrow Transplantation, 2020, 55, 1604-1613.	1.3	147
271	Long-term outcomes and risk factor analysis of steroid-refractory graft versus host disease after hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 38-49.	1.3	9
272	Acute Graft-versus-Host-Disease Other Than Typical Targets: Between Myths and Facts. Transplantation and Cellular Therapy, 2021, 27, 115-124.	0.6	13
273	Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation. Journal of Thrombosis and Thrombolysis, 2021, 51, 854-869.	1.0	20
274	The Role of Hematopoietic Stem Cell Transplantation in CML. Hematologic Malignancies, 2021, , 159-178.	0.2	0

#	Article	IF	Citations
276	The hemogenic endothelium: a critical source for the generation of PSC-derived hematopoietic stem and progenitor cells. Cellular and Molecular Life Sciences, 2021, 78, 4143-4160.	2.4	25
277	Immunotherapy for Hematologic Malignancies. Journal of Clinical Oncology, 2021, 39, 343-345.	0.8	6
278	Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplantation, 2021, 56, 1651-1664.	1.3	221
279	Low-dose decitabine for refractory prolonged isolated thrombocytopenia after HCT: a randomized multicenter trial. Blood Advances, 2021, 5, 1250-1258.	2.5	9
281	Post-Transplant Cyclophosphamide and Tacrolimusâ€"Mycophenolate Mofetil Combination Governs GVHD and Immunosuppression Need, Reducing Late Toxicities in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors. Journal of Clinical Medicine, 2021, 10, 1173.	1.0	10
282	Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?. Frontiers in Immunology, 2021, 12, 659595.	2.2	44
283	Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves. Transplantation and Cellular Therapy, 2021, 27, 438.e1-438.e6.	0.6	11
284	JAK-STAT in Early Hematopoiesis and Leukemia. Frontiers in Cell and Developmental Biology, 2021, 9, 669363.	1.8	29
285	FDG PET for Assessment of Autologous Stem Cell Transplantation. Seminars in Nuclear Medicine, 2021, 51, 380-391.	2.5	4
286	Glueless and Sutureless Multi-Layer Amniotic Membrane Transplantation in a Patient With Pending Corneal Perforation. Cureus, 2021, 13, e16678.	0.2	3
287	Clinical and basic implications of dynamic T cell receptor clonotyping in hematopoietic cell transplantation. JCI Insight, 2021, 6, .	2.3	12
288	Post-Irradiation Hyperamylasemia Is a Prognostic Marker for Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in Pediatric Population: A Retrospective Single-Centre Cohort Analysis. Journal of Clinical Medicine, 2021, 10, 3834.	1.0	0
289	Purinergic Signalling in Allogeneic Haematopoietic Stem Cell Transplantation and Graft-versus-Host Disease. International Journal of Molecular Sciences, 2021, 22, 8343.	1.8	9
290	Mussel-Inspired Catechol Functionalisation as a Strategy to Enhance Biomaterial Adhesion: A Systematic Review. Polymers, 2021, 13, 3317.	2.0	16
291	Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation. Cellular and Molecular Immunology, 2021, 18, 1172-1185.	4.8	55
292	History of Bone Marrow Transplantation. Organ and Tissue Transplantation, 2021, , 3-26.	0.0	0
293	Outcomes of Bone Marrow Transplantation. Organ and Tissue Transplantation, 2021, , 689-730.	0.0	0
294	Normal Hematopoiesis and Blood Cell Maturation. , 2021, , 1-12.		0

#	Article	IF	Citations
295	Regenerative Medicine at a Global Level: Current Patterns and Global Trends. , 2013, , 18-57.		3
296	Are we making progress in GVHD prophylaxis and treatment?. Hematology American Society of Hematology Education Program, 2012, 2012, 251-64.	0.9	37
297	What Is Regenerative Medicine?. , 2016, , 19-24.		1
298	Examining the Feasibility of Clinical Grade CD271+ Enrichment of Mesenchymal Stromal Cells for Bone Regeneration. PLoS ONE, 2015, 10, e0117855.	1.1	44
299	Commonly used mesenchymal stem cell markers and tracking labels: Limitations and challenges. Histology and Histopathology, 2013, 28, 1109-16.	0.5	156
300	IN TIME: IMPORTÃ‚NCIA E IMPLICAÃ‡Ã•ES GLOBAIS DATRIAGEM NEONATAL PARA A IMUNODEFICIÃŠNCIA GRAVE COMBINADA. Revista Paulista De Pediatria, 2018, 36, 388-397.	0.4	2
301	Caring Process in Hematopoietic Stem Cell Transplantation: A Grounded Theory Study. International Journal of Hematology-Oncology and Stem Cell Research, 0, , .	0.3	2
302	Transforming growth factor-Î²1 polymorphisms and graft-versus-host disease risk: a meta-analysis. Oncotarget, 2016, 7, 2455-2461.	0.8	6
303	Bending the Productivity Curve: Why America Leads the World in Medical Innovation. SSRN Electronic Journal, 0, , .	0.4	15
304	Innate Immune Determinants of Graft-Versus-Host Disease and Bidirectional Immune Tolerance in Allogeneic Transplantation. OBM Transplantation, 2019, 3, 1-1.	0.2	2
305	Hematopietic Stem Cell Transplantation in Thalassemia and Related Disorders. Mediterranean Journal of Hematology and Infectious Diseases, 2009, 1, e2009015.	0.5	3
306	Blood and Bone Marrow Transplantation in India: Past, Present, and Future. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 308-311.	0.1	8
307	Ex vivo expansion of hematopoietic stem cells: mission accomplished?. Swiss Medical Weekly, 2011, 141, w13316.	0.8	20
308	Haematopoietic stem cell transplantation: activity in Switzerland compared with surrounding European countries. Swiss Medical Weekly, 2013, 143, w13757.	0.8	4
309	Autologous Noncryopreserved Hematopoietic Stem Cell Transplant With CEAM as a Modified Conditioning Regimen in Patients With Hodgkin Lymphoma: A Single-center Experience With a New Protocol. Experimental and Clinical Transplantation, 2012, 10, 163-167.	0.2	22
310	Effects of targeted education for first-year university students on knowledge and attitudes about stem cell transplantation and donation. Experimental and Clinical Transplantation, 2015, 13, 76-81.	0.2	10
311	HLA Genotypes in Turkish Hematopoietic Cell Recipients and Likelihood of Finding a Matched Donor Through Family Searches. Experimental and Clinical Transplantation, 2019, 17, 813-818.	0.2	4
313	Chronic myeloid leukemia. , 2008, , 1-16.		0

#	Article	IF	Citations
314	Minimal Residual Disease. , 2010, , 667-685.		0
316	Challenges of Taking Embryonic Stem Cells from Bench to Clinic. , 2010, , 185-208.		0
317	What Is Regenerative Medicine?. , 2010, , 3-8.		0
318	Chronic Myeloid Leukemia. , 2011, , 853-853.		0
321	Kapitel E1 Literaturverzeichnis zu Peter, Pichler, MÃ¼ller-Ladner (Hrsg.): Klinische Immunologie. , 2012, , e1-e80.		0
322	Can Allogeneic Hematopoietic Cell Transplantation Outcome be Improved by Intravenous Apoptotic Cell Infusion?. Journal of Cell Science & Therapy, 2013, 04, .	0.3	0
324	Infection Control and Hospital Epidemiology in Hematology Units. , 2015, , 297-313.		0
325	Recent Patents on Perinatal Stem Cells. , 2014, , 361-369.		0
326	Difficulty in respirator weaning of a patient having central sleep apnea syndrome. Journal of the Japanese Society of Intensive Care Medicine, 2015, 22, 217-218.	0.0	0
328	Phagocytes Defects. , 2017, , 245-294.		3
329	Exercise Perception during Hematopoietic Transplantation for Hematological Cancer Patients. Korean Journal of Sport Studies, 2017, 56, 527-540.	0.1	0
330	Hematopoetik KÃ¶k HÃ¼cre Transplantasyonu ve Ã‡ocuklardaki KazanÄ±lmÄ±ÅŸ Aplastik Anemi Tedavisinde Transplantasyonun Yeri. Turkish Journal of Pediatric Disease, 0, , 1-2.	0.0	0
331	Multipotent mesenchymal stem cells in renal transplantation. TransplantologiÃ¢, 2019, 11, 21-36.	0.1	0
332	Cytomegalovirus Infection Downregulates Vitamin D Receptor in Patients Undergoing Hematopoietic Stem Cell Transplantation. Transplantation, 2021, 105, 1595-1602.	0.5	7
333	Outcomes of Bone Marrow Transplantation. Organ and Tissue Transplantation, 2020, , 1-43.	0.0	0
335	Greffe de cellules souches hÃ©matopoÃ¯Ã©tiques. , 2020, , 293-296.e1.		0
336	History of Bone Marrow Transplantation. Organ and Tissue Transplantation, 2020, , 1-24.	0.0	0
337	Prognostic factors of pediatric hematopoietic stem cell transplantation recipients admitted to the pediatric intensive care unit. Acute and Critical Care, 2021, 36, 380-387.	0.6	2

#	Article	IF	Citations
338	Caring Process in Hematopoietic Stem Cell Transplantation: A Grounded Theory Study. International Journal of Hematology-Oncology and Stem Cell Research, 2019, 13, 83-94.	0.3	0
339	Assessment of haematopoietic progenitor cell counting with the Sysmex XN-1000 to guide timing of apheresis of peripheral blood stem cells. Blood Transfusion, 2020, 18, 67-76.	0.3	2
340	Plasma levels of norepinephrine and expression levels of ÃŸ2-adrenergic receptor gene correlate with the incidence of acute graft-versus-host disease. Medical Journal of the Islamic Republic of Iran, 2020, 34, 151.	0.9	2
341	Randomized Phase III BMT CTN Trial of Calcineurin Inhibitorâ€“Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. Journal of Clinical Oncology, 2022, 40, 356-368.	0.8	79
342	Current State and Issues of Regenerative Medicine for Rheumatic Diseases. Frontiers in Medicine, 2022, 9, 813952.	1.2	3
343	Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on â€œOff-the-Shelfâ€•T Cell Therapy Using iPSC Technology and Gene Editing. Cells, 2022, 11, 269.	1.8	10
344	Comparable anti-CMV responses of transplant donor and third-party CMV-specific T cells for treatment of CMV infection after allogeneic stem cell transplantation. Cellular and Molecular Immunology, 2022, 19, 482-491.	4.8	15
345	Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey. Bone Marrow Transplantation, 2022, 57, 742-752.	1.3	45
346	Role of the Endothelium in Neonatal Diseases. , 2022, 1, 44-57.		1
347	Managing a bone marrow transplant centre to maximise patients' health benefits. International Journal of Production Research, 0, , 1-25.	4.9	0
350	Hematopoietic Cell Procurement, Processing, and Transplantation: Standards, Accreditation, and Regulation. , 0, , 533-543.		0
355	Current insights into the bone marrow niche: From biology in vivo to bioengineering ex vivo. Biomaterials, 2022, 286, 121568.	5.7	16
356	Multiomics Analysis Identifies SOCS1 as Restraining T Cell Activation and Preventing Graftâ€Versusâ€Host Disease. Advanced Science, 2022, 9, e2200978.	5.6	7
357	Impact of Nanotechnology on the Realm of Stem Cells and Regenerative Medicine. ChemNanoMat, 2022, 8, .	1.5	0
358	Blood Stem Cell Donation: A Model for Worldwide Cooperation in Transplantation. Annals of the Academy of Medicine, Singapore, 2014, 43, 294-295.	0.2	1
359	Incidence of chronic renal injury in patients undergoing autologous stem cell transplant therapy. Internal Medicine Journal, 2023, 53, 1170-1179.	0.5	0
360	Oral active matrix metalloproteinaseâ€8 immunotest may be less accurate in haematoâ€oncologic patients. Oral Diseases, 0, , .	1.5	0
361	Lactate dehydrogenase as a hematopoietic stem cell mobilization biomarker in autologous transplantation. Hematology, Transfusion and Cell Therapy, 2022, , .	0.1	0

#	Article	IF	Citations
363	Pediatric hematopoietic stem cell transplantation in Serbia - 25 years of experience. Medicinski Pregled, 2022, 75, 50-53.	0.1	0
365	Cardiovascular Complications in Hematopoietic Stem Cell Transplanted Patients. Journal of Personalized Medicine, 2022, 12, 1797.	1.1	5
366	Nanoparticles targeting hematopoietic stem and progenitor cells: Multimodal carriers for the treatment of hematological diseases. Frontiers in Genome Editing, 0, 4, .	2.7	3
367	Molecular mechanisms of exercise contributing to tissue regeneration. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	24
368	High ME1 Expression Is a Molecular Predictor of Post-Transplant Survival of Patients with Acute Myeloid Leukemia. Cancers, 2023, 15, 296.	1.7	1
369	Role of abatacept in the prevention of graft-versus-host disease: current perspectives. Therapeutic Advances in Hematology, 2023, 14, 204062072311526.	1.1	1
370	Immunotherapy for Hematological Cancers. , 2023, , 1-15.		0
371	Medical emergencies in pediatric blood & marrow transplant and cellular therapies. Frontiers in Pediatrics, 0, 11, .	0.9	1
372	Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey. Bone Marrow Transplantation, 2023, 58, 647-658.	1.3	11
373	Defibrotide impact on the acute GVHD disease incidence in pediatric hematopoietic stem cell transplant recipients. Life Science Alliance, 2023, 6, e202201786.	1.3	1
382	Stem Cell-Based Regenerative Medicine Therapy in Cancer. , 2023, , 1-21.		0
386	Metabolism in Hematopoiesis and Its Malignancy. Advances in Experimental Medicine and Biology, 2023, , 45-64.	0.8	0
388	Introduction on Stem Cell Therapy and Regeneration. , 2024, , .		0